A股異動 | 東曜藥業升超9% 核心產品銷售業績大幅增長
東曜藥業(1875.HK)升超9%,報1.82港元,總市值14.06億港元。消息上,此前東曜藥業發佈的中期報吿顯示,上半年實現營收3.28億元(人民幣,下同),同比增長80%。因2023年上半年無一次性授權金收入(去年同期為4943.4萬元),剔除該因素影響,2023年上半年收入增長達147%。其中,銷售收入為2.78億元,同比增長167%,這主要貢獻來自於核心產品樸欣汀銷售業績的大幅增長。CDMO/CMO業務收入4654.6萬元,同比增長105%。報吿提到,在技術方面,公司持續打造領先的ADC CDMO技術平台。2023年,公司與糖嶺生物開展合作,共同開發 DisacLink™ ADC糖定點偶聯技術平台,打造全球最具應用價值定點偶聯技術,賦能ADC創新藥加速發展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.